GlassScriptPhysician profile
Johnny Lee Williams
NPI 1972697746
$3,130.92
in general payments reported to CMS, 2019-2025
17 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Addiction Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $152).
See the full distribution for Addiction Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $736 · 2021: $791 · 2022: $328 · 2024: $225 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $508.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $819.64 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $472.55 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $362.47 | 2020-2024 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $236.60 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $231.13 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $159.59 | 2020-2025 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $130.40 | 2019-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $124.19 | 2019-2025 | Rexulti |
| Eisai INC. | $116.20 | 2021 | |
| Allergan, INC. | $115.15 | 2019-2020 | |
| Alkermes, INC. | $92.49 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $91.79 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.57 | 2024-2025 | Trintellix |
| Abbvie INC. | $56.54 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $38.79 | 2024-2025 | Cobenfy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $14.45 | 2019 | |
| Indivior INC. | $12.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnny Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.